IL10 and Cowden disease: Recombinant human IL-10 raised hope when first used in the 90s in CD patients as the treatment led to remission in patients that were otherwise refractory to treatment [6]; however, two large, multi-centered follow-up studies using subcutaneous dosing were unable to confirm the results [7,8].